A citation-based method for searching scientific literature

Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
Times Cited: 358







List of co-cited articles
938 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
454
53

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
481
44

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y Yeap, Lynette M Sholl, Bruce E Johnson, Pasi A Jänne. Clin Cancer Res 2013
234
43

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paul K Paik, Maria E Arcila, Michael Fara, Camelia S Sima, Vincent A Miller, Mark G Kris, Marc Ladanyi, Gregory J Riely. J Clin Oncol 2011
457
39

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
260
30

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.
Anya M Litvak, Paul K Paik, Kaitlin M Woo, Camelia S Sima, Matthew D Hellmann, Maria E Arcila, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely. J Thorac Oncol 2014
82
34

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle,[...]. J Thorac Oncol 2015
113
25

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
25

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Claire Tissot, Sébastien Couraud, Ronan Tanguy, Pierre-Paul Bringuier, Nicolas Girard, Pierre-Jean Souquet. Lung Cancer 2016
87
28

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
418
23

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Liza C Villaruz, Mark A Socinski, Shira Abberbock, Lynne D Berry, Bruce E Johnson, David J Kwiatkowski, A John Iafrate, Marileila Varella-Garcia, Wilbur A Franklin, D Ross Camidge,[...]. Cancer 2015
77
28

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban,[...]. J Thorac Oncol 2018
97
22

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
22

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
21

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
21

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
20

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
20

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
19


First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
19

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
18

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard. Cancer Treat Rev 2018
68
26

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
J Mazieres, C Cropet, L Montané, F Barlesi, P J Souquet, X Quantin, C Dubos-Arvis, J Otto, L Favier, V Avrillon,[...]. Ann Oncol 2020
59
30

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
99
18

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
17

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
17

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, Chiara Ambrogio, Lorin A Ferris, Christine Lydon, Tom Nguyen, Nicholas A Jessop, A John Iafrate, Bruce E Johnson,[...]. Clin Cancer Res 2019
51
33

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
17

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
16

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, Didier Debieuvre, Jean Mosser, Hervé Lena, L'Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel,[...]. Lancet 2016
557
15

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
15

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
624
15

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Matthew Dankner, April A N Rose, Shivshankari Rajkumar, Peter M Siegel, Ian R Watson. Oncogene 2018
165
15

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Zhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, Anthony Tao, Neilawattie M Torres, Matthew T Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough,[...]. Nature 2017
264
14

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
14

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
278
14

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
428
14

Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Xi Ding, Zengli Zhang, Tao Jiang, Xuefei Li, Chao Zhao, Bo Su, Caicun Zhou. Cancer Med 2017
30
46

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
369
14

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
13

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
901
13

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
13

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
363
13

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.
Anna F Farago, Martin S Taylor, Robert C Doebele, Viola W Zhu, Shivaani Kummar, Alexander I Spira, Theresa A Boyle, Eric B Haura, Maria E Arcila, Ryma Benayed,[...]. JCO Precis Oncol 2018
100
13

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
855
13

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Christina S Baik, Nathaniel J Myall, Heather A Wakelee. Oncologist 2017
67
17

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Zhan Yao, Neilawattie M Torres, Anthony Tao, Yijun Gao, Lusong Luo, Qi Li, Elisa de Stanchina, Omar Abdel-Wahab, David B Solit, Poulikos I Poulikakos,[...]. Cancer Cell 2015
262
12

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
T Kinno, K Tsuta, K Shiraishi, T Mizukami, M Suzuki, A Yoshida, K Suzuki, H Asamura, K Furuta, T Kohno,[...]. Ann Oncol 2014
90
13

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
351
12

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.